Breaking News

Fujifilm Diosynth Licenses Oxgene’s AAV system

Aims to deliver gene therapy products to clients with an approximate 25% lead-time reduction

By: Contract Pharma

Contract Pharma Staff

Fujifilm Diosynth Biotechnologies (FDB) has entered a strategic partnership with Oxgene, a developer of gene therapy technologies. FDB has licensed Oxgene’s AAV system for commercial use to support biotech companies with gene therapy development and manufacture. The partnership aims to enable FDB to deliver gene therapy products to clients with an approximate 25% lead-time reduction. The AAV system consists of Helper, Rep/Cap and Gene of Interest plasmids, used in combination with a clo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters